Scott Tomlins, MD, Ph.D. Co-Founder, and Chief Scientific Officer - Strata discusses the Strata Oncology Partners with Elevation Oncology to Accelerate Enrollment of CRESTONE Study for Patients with Rare NRG1 Gene Fusions.
Press Release -
ANN ARBOR, Mich., July 21, 2020 / PRNewswire/ — Strata Oncology, Inc., a precision oncology company developing molecular targets for cancer therapies, today announced the signing of an agreement with the newly launched Elevation Oncology to facilitate patient detection and registration for the Phase 2 CRESTONE Elevation Oncology trial evaluating seribantumab use in recurrent patients;
Seribantumab is a fully human monoclonal IgG2 antibody that binds to receptor 3 (ERBB3 or HER3) of the human epidermal growth factor. The CRESTONE research draws on previous clinical experience from more than 800 patients with clear protection and tolerability. NRG1 gene fusions are oncogenic drivers that can be detected in a number of solid tumors including lung, pancreatic, gallbladder, breast, ovarian, colorectal, and neuroendocrine cancers, and sarcomas.
According to Shawn Leland, PharmD, RPh, Creator and Chief Medical Officer of Elevation Oncology, developments in molecular testing of tumors have provided an opportunity to develop how we interpret genomic alterations and determine the best therapies for individuals. Collaboration between diagnostic providers and drug developers is vital to obtaining the best results for patients with unusual, genomically induced cancers such as fusions of the NRG1 genes.
Under the terms of the agreement, for consideration of inclusion in the CRESTONE study by Elevation Oncology, Strata Oncology will recognize patients with advanced solid tumors that harbor the NRG1 gene fusion and meet other eligibility criterias.
This relationship exemplifies Strata Oncology 's dedication to creating a future where each cancer patient receives their best care possible, said Dan Rhodes, Ph.D., Strata Oncology 's CEO. NRG1 fusions are uncommon oncogenic drivers that occur through many types of tumors, such as lung and pancreatic, and patients with these cancers are mostly treated in community oncology centers making good use of vital tissue samples. Through system-wide distribution of StrataNGSTM, our tumor-optimized molecular profiling test for small tissue samples, we believe our nationwide network of health systems can help drive patient recognition and enrollment into this critical research.
A recent research presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting in 2020 showed an increased proportion of patients with actionable biomarkers due to StrataNGS results on small tissue samples. Results from a Strata Trial data review showed that less than half of the > 20,000 formalin-fixed paraffin-embedded (FFPE) tumor tissue samples met tumor surface area criteria for leading commercial comprehensive genomic profiling (CGP) hybrid-capture-based studies. In 96 percent of all samples collected, StrataNGS, a PCR-CGP test, successfully recorded findings.
For more on the CRESTONE report, please visit www. NRG1fusion.com